These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 12442020)

  • 1. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa.
    Huebner RE; Mbelle N; Forrest B; Madore DV; Klugman KP
    Pediatr Infect Dis J; 2002 Nov; 21(11):1004-7. PubMed ID: 12442020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.
    O'Brien KL; Swift AJ; Winkelstein JA; Santosham M; Stover B; Luddy R; Gootenberg JE; Nold JT; Eskenazi A; Snader SJ; Lederman HM
    Pediatrics; 2000 Nov; 106(5):965-72. PubMed ID: 11061761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants.
    Puumalainen T; Zeta-Capeding MR; Käyhty H; Lucero MG; Auranen K; Leroy O; Nohynek H
    Pediatr Infect Dis J; 2002 Apr; 21(4):309-14. PubMed ID: 12075762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
    Shinefield HR; Black S; Ray P; Chang I; Lewis N; Fireman B; Hackell J; Paradiso PR; Siber G; Kohberger R; Madore DV; Malinowski FJ; Kimura A; Le C; Landaw I; Aguilar J; Hansen J
    Pediatr Infect Dis J; 1999 Sep; 18(9):757-63. PubMed ID: 10493334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine.
    Huebner RE; Mbelle N; Forrest B; Madore DV; Klugman KP
    Vaccine; 2004 Jul; 22(21-22):2696-700. PubMed ID: 15246599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants.
    Nurkka A; Joensuu J; Henckaerts I; Peeters P; Poolman J; Kilpi T; Käyhty H
    Pediatr Infect Dis J; 2004 Nov; 23(11):1008-14. PubMed ID: 15545855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
    Platt HL; Greenberg D; Tapiero B; Clifford RA; Klein NP; Hurley DC; Shekar T; Li J; Hurtado K; Su SC; Nolan KM; Acosta CJ; McFetridge RD; Bickham K; Musey LK;
    Pediatr Infect Dis J; 2020 Aug; 39(8):763-770. PubMed ID: 32639460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.
    Rennels MB; Edwards KM; Keyserling HL; Reisinger KS; Hogerman DA; Madore DV; Chang I; Paradiso PR; Malinoski FJ; Kimura A
    Pediatrics; 1998 Apr; 101(4 Pt 1):604-11. PubMed ID: 9521941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
    Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus-conjugated vaccine: a randomized controlled trial.
    Lucero MG; Puumalainen T; Ugpo JM; Williams G; Käyhty H; Nohynek H
    J Infect Dis; 2004 Jun; 189(11):2077-84. PubMed ID: 15143476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants.
    Jones SA; Groome M; Koen A; Van Niekerk N; Sewraj P; Kuwanda L; Izu A; Adrian PV; Madhi SA
    PLoS One; 2013; 8(8):e72794. PubMed ID: 24015277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in Taiwanese infants.
    Shao PL; Lu CY; Chang LY; Huang FY; Wang CY; Yang CY; Wu TZ; Lee CY; Huang LM
    J Formos Med Assoc; 2004 Aug; 103(8):613-7. PubMed ID: 15340660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial.
    van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
    Pediatr Infect Dis J; 2016 Jul; 35(7):e206-19. PubMed ID: 27097348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine.
    Sigurdardottir ST; Ingolfsdottir G; Davidsdottir K; Gudnason T; Kjartansson S; Kristinsson KG; Bailleux F; Leroy O; Jonsdottir I
    Pediatr Infect Dis J; 2002 Jun; 21(6):548-54. PubMed ID: 12182380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.